このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

初期アルツハイマー病の参加者におけるJNJ-63733657の研究 (Autonomy)

2026年10月14日 更新者:Janssen Research & Development, LLC

初期アルツハイマー病の参加者における抗タウモノクローナル抗体であるJNJ-63733657の有効性と安全性を評価するための無作為化二重盲検プラセボ対照並行群多施設研究

The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognition and function.

調査の概要

研究の種類

介入

入学 (実際)

523

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35233
        • University of Alabama Birmingham
    • Arizona
      • Phoenix、Arizona、アメリカ、85013
        • Dignity Health
    • California
      • Irvine、California、アメリカ、92614
        • Irvine Clinical Research
      • La Jolla、California、アメリカ、92037
        • University of California San Diego Medical Center
      • Los Angeles、California、アメリカ、90095
        • University of California - Los Angeles
      • Palo Alto、California、アメリカ、94304
        • Stanford University Medical Center
      • San Diego、California、アメリカ、92103
        • Pacific Research Network Prn
      • Santa Ana、California、アメリカ、92705
        • Syrentis Clinical Research
    • Connecticut
      • New Haven、Connecticut、アメリカ、06510
        • Yale University School Of Medicine
    • District of Columbia
      • Washington D.C.、District of Columbia、アメリカ、20007
        • Georgetown University Clinical Research Unit CRU
    • Florida
      • Atlantis、Florida、アメリカ、33462
        • JEM Research LLC
      • Delray Beach、Florida、アメリカ、33445
        • Brain Matters Research
      • Fort Myers、Florida、アメリカ、33912
        • Neuropsychiatric Research Center of SWFL
      • Jacksonville、Florida、アメリカ、32256
        • Clinical NeuroScience Solutions Inc
      • Jupiter、Florida、アメリカ、33458
        • Alphab Global Research
      • Maitland、Florida、アメリカ、32751
        • K2 Medical Research
      • Maitland、Florida、アメリカ、32751
        • Tandem Intermediate LLC
      • Merritt Island、Florida、アメリカ、32952
        • Merritt Island Medical Research, LLC
      • Miami、Florida、アメリカ、33136
        • University of Miami Miller School of Medicine
      • Miami、Florida、アメリカ、33137
        • Miami Jewish Health System
      • Naples、Florida、アメリカ、34105
        • Aqualane Clinical Research
      • Ocala、Florida、アメリカ、34470
        • Renstar Medical Research
      • Ocoee、Florida、アメリカ、34761
        • Sensible Healthcare
      • Tampa、Florida、アメリカ、33609
        • Axiom Clinical Research of Florida
      • Tampa、Florida、アメリカ、33613
        • Stedman Clinical Trials
      • Tampa、Florida、アメリカ、33613
        • University of South Florida - Health Byrd Alzheimer Institute
      • The Villages、Florida、アメリカ、32162
        • Charter Research
      • Viera、Florida、アメリカ、32904
        • ClinCloud Clinical Research
      • Wellington、Florida、アメリカ、33414
        • Alzheimers Research and Treatment Center
      • West Palm Beach、Florida、アメリカ、33407
        • Palm Beach Neurology and Premier Research Institute
      • Winter Park、Florida、アメリカ、32789
        • Conquest Research
    • Georgia
      • Atlanta、Georgia、アメリカ、30329
        • The Emory Clinic
      • Decatur、Georgia、アメリカ、30030
        • Sandhill Research
    • Illinois
      • Chicago、Illinois、アメリカ、60640
        • Great Lakes Clinical Trials
      • Elk Grove Village、Illinois、アメリカ、60007
        • Alexian Brothers Medical Center - Neuroscience Research Institute
    • Indiana
      • Indianapolis、Indiana、アメリカ、46202
        • Indiana University
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • Beth Israel Deaconess Medical Center
      • Boston、Massachusetts、アメリカ、02114
        • Massachusetts General Hospital
      • Braintree、Massachusetts、アメリカ、02184
        • Anil Nair dba Alzheimer's Disease Center
    • Mississippi
      • Hattiesburg、Mississippi、アメリカ、39401
        • Hattiesburg Clinic
    • Missouri
      • St Louis、Missouri、アメリカ、63110
        • Washington University School Of Medicine
    • New Jersey
      • Mount Arlington、New Jersey、アメリカ、07856
        • NeuroCognitive Institute
      • Princeton、New Jersey、アメリカ、08540
        • Princeton Medical Institute
      • Toms River、New Jersey、アメリカ、08755
        • Advanced Memory Research Institute of NJ
    • New York
      • Albany、New York、アメリカ、12208
        • Neurological Associates of Albany, PC
      • East Syracuse、New York、アメリカ、13057
        • Velocity Clinical Research
      • New York、New York、アメリカ、10016
        • New York University Medical Center
    • North Carolina
      • Winston-Salem、North Carolina、アメリカ、27157
        • Wake Forest Health Sciences
    • Ohio
      • Cleveland、Ohio、アメリカ、44195
        • Cleveland Clinic Lou Revo Center for Brain Health
      • Columbus、Ohio、アメリカ、43221
        • Wexner Medical Center at the Ohio State University
    • Pennsylvania
      • Plymouth Meeting、Pennsylvania、アメリカ、19462
        • Keystone Clinical Studies LLC
    • Rhode Island
      • Providence、Rhode Island、アメリカ、02906
        • Brown University School of Medicine
    • Texas
      • Houston、Texas、アメリカ、77054
        • The University of Texas Health Science Center at Houston
    • Vermont
      • Bennington、Vermont、アメリカ、05201
        • Memory Clinic Inc
    • Virginia
      • Charlottesville、Virginia、アメリカ、22903
        • University of Virginia
      • Bath、イギリス、BA1 3NG
        • Royal United Hospital
      • London、イギリス、W6 8RF
        • Charing Cross Hospital
      • 's-Hertogenbosch、オランダ、5223 LA
        • BRC - Den Bosch
      • Amsterdam、オランダ、1081 GN
        • BRC - Amsterdam
      • Leeuwarden、オランダ、8934AD
        • QPS Netherlands
      • Zwolle、オランダ、8052 AZ
        • BRC Zwolle
      • Adelaide、オーストラリア、5000
        • Royal Adelaide Hospital
      • Box Hill、オーストラリア、3128
        • Box Hill Hospital
      • Carlton、オーストラリア、3053
        • Neuro Trials Victoria
      • Ivanhoe、オーストラリア、3079
        • Austin Health
      • Malvern、オーストラリア、3144
        • HammondCare Neurodegenerative Clinical Trials - VIC
      • Nedlands、オーストラリア、6009
        • Australian Alzheimer's Research Foundation Incorporated
      • Parkville、オーストラリア、3050
        • Royal Melbourne Hospital
    • Ontario
      • London、Ontario、カナダ、N6C 0A7
        • Parkwood Institute
      • Peterborough、Ontario、カナダ、K9H 2P4
        • Kawartha Centre - Redefining Healthy Aging
      • Toronto、Ontario、カナダ、M3B 257
        • Toronto Memory Program (Neurology Research Inc.)
      • Toronto、Ontario、カナダ、M5T 2S8
        • UHN-Toronto Western Hospital
    • Quebec
      • Montreal、Quebec、カナダ、H3A 2B4
        • McGill University
      • Stockholm、スウェーデン、14186
        • Karolinska Universitetssjukhuset
      • Algorta - Getxo、スペイン、48993
        • Centro At. Esp. Oroitu
      • Barcelona、スペイン、08025
        • Hosp. de La Santa Creu I Sant Pau
      • Barcelona、スペイン、08003
        • Hosp. Del Mar
      • Barcelona、スペイン、08028
        • Fund. Ace-Inst. Cat. Neuroc. Aplicades
      • Barcelona、スペイン、08195
        • Idc Salud Hosp. Gral. de Catalunya
      • Lleida、スペイン、25198
        • Hosp. Univ. Santa Maria
      • Madrid、スペイン、28040
        • Hosp. Clinico San Carlos
      • Terrassa、スペイン、08221
        • Hosp. Mutua Terrassa
      • Valencia、スペイン、46026
        • Hosp. Univ. I Politecni La Fe
      • Bordeaux、フランス、33076
        • Hopital Pellegrin CHU Bordeaux
      • Lille、フランス、59037
        • Hopital Roger Salengro - CHU Lille
      • Nantes、フランス、44093
        • CHU Nantes - Hopital Nord Laënnec
      • Paris、フランス、75010
        • Hopital Lariboisiere-Fernand Widal
      • Paris、フランス、75013
        • Hopital Pitie Salpetriere
      • Rennes、フランス、35009
        • Chu Rennes Hopital Pontchaillou
      • Rouen、フランス、76031
        • Hopital Charles Nicolle
      • Toulouse、フランス、31059
        • CHU Toulouse - Hôpital La Grave
      • Tours、フランス、37000
        • Hôpital Bretonneau
      • Bruges、ベルギー、8000
        • AZ St.-Jan Brugge-Oostende AV
      • Brussels、ベルギー、1200
        • UCL Hopital Saint-Luc
      • Edegem、ベルギー、2650
        • UZ Antwerpen
      • Ghent、ベルギー、9000
        • Universitair Ziekenhuis Gent
      • Hasselt、ベルギー、3500
        • Jessa Ziekenhuis
      • Jette、ベルギー、1090
        • UZ Brussel
      • Leuven、ベルギー、3000
        • UZ Leuven
      • Roeselare、ベルギー、8800
        • Algemeen Ziekenhuis Delta
      • Aizu-Wakamatsu、日本、965-8585
        • Takeda General Hospital
      • Chiba、日本、263-0043
        • Inage Neurology and Memory Clinic
      • Fujisawa-shi、日本、251-0038
        • Kawashima Neurology Clinic
      • Fukuoka、日本、814-0180
        • Fukuoka University Hospital
      • Hachiōji、日本、192-0071
        • Keikokai P-One Clinic
      • Himeji、日本、672-8043
        • Himeji Central Hospital Clinic
      • Kamakura-shi、日本、247-8533
        • Shonan Kamakura General Hospital
      • Kanzaki-gun、日本、842-0192
        • National Hospital Organization Hizen Psychiatric Center
      • Kawasaki、日本、210-0852
        • Koukan Clinic
      • Kobe、日本、650-0047
        • Kobe City Medical Center General Hospital
      • Kurashiki-shi、日本、7100813
        • Rijikai Medical Corporation Katayama Medical Clinic
      • Kurume、日本、830-0011
        • Kurume University Hospital
      • Kyoto、日本、607-8062
        • Rakuwakai Otowa Hospital
      • Kyoto、日本、607-8113
        • Rakuwakai Otowa Rehabilitation Hospital
      • Narashino、日本、275-0006
        • Saiseikai Narashino Hospital
      • Obu-shi、日本、474-8511
        • National Center For Geriatrics And Gerontology
      • Shinjuku-ku、日本、162-0053
        • Clinical Research Hospital Tokyo
      • Tokyo、日本、160-0023
        • Tokyo Medical University Hospital
      • Tokyo、日本、173-0015
        • Tokyo Metropolitan Geriatric Hospital
      • Toyonaka-shi、日本、560-0004
        • Nagomi Clinic
      • Toyonaka-shi、日本、5600004
        • Jinsenkai MI Clinic
      • Yokohama、日本、235-0012
        • Yokohama Brain and Spine Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

55年~80年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Early Alzheimer's disease (AD): Gradual and progressive subjective decline in the participant's cognition over at least the past 6 months, as reported by the participant and informant (study partner) and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 and memory box score greater than or equal to (>=) 0.5 at screening
  • Participants must have positive tau PET results
  • Able to read and write and with a minimum 5 years of formal education as reported by participant and study partner at screening
  • Have a designated study partner who has adequate literacy to participate and be judged to have high likelihood of completing the study with the participant
  • Male participants must agree not to donate sperm for the purpose of reproduction during the study and up to 16 weeks after receiving the last dose of study intervention

Exclusion Criteria:

  • Participants with CDR GS >=2 at predose baseline Clinical Dementia Rating (CDR) administration
  • Participants who fulfill diagnostic criteria for Mild Cognitive Impairment (MCI) or dementia/mild or major neurocognitive disorder suspected to be due to any etiology other than AD (example, Parkinson's disease, cerebrovascular disease, normal pressure hydrocephalus, head injury, drug or alcohol abuse/dependence, anoxic brain injury, (Et cetera[etc])
  • Geriatric Depression Scale (GDS) 30 score greater than (>) 12
  • Hachinski Ischemic Scale (HIS) >4
  • Has received medications that affect the central nervous system (CNS), except treatments for AD, for less than 2 months; that is, doses of chronic medications that effect the CNS should be stable for at least 2 months before the start of screening. If a participant has recently stopped a chronic medication that effects the CNS, he or she must have discontinued treatment at least 2 months before the start of screening. Chronic use of benzodiazepines is not permitted

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:JNJ-63733657 Low-dose

Participants will receive single dose of JNJ-63733657 low-dose administered by intravenous (IV) infusion every 4 weeks during the double-blind treatment period. Participants will have an option to continue with the long-term extension (LTE) phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period.

JNJ-63733657 low or high dose will be administered by IV infusion.

実験的:JNJ-63733657 High-dose

Participants will receive single dose of JNJ-63733657 high-dose administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period.

JNJ-63733657 low or high dose will be administered by IV infusion.

プラセボコンパレーター:Placebo

Participants will receive single dose of matching placebo to JNJ-63733657 administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will be re-randomized in a 1:1 ratio to receive either JNJ-63733657 low-dose or JNJ-63733657 high-dose during the LTE treatment period.

Placebo matching to JNJ-63733657 will be administered by IV infusion.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Double-blind (DB) Treatment Period: Change From Baseline in Integrated Alzheimer's Disease Rating Scale for Mild Cognitive Impairment (iADRS-MCI) Total Score at Week 104
時間枠:Baseline (Day 1), Week 104

The iADRS-MCI was a composite measure of cognition and function. It was originally developed as a combination of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) 14-item cognition subscale and the instrumental activities of daily living (ADL) items from the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scale. It was calculated as a linear combination of total scores of the 2 individual components. The iADRS-MCI total score was derived as a combination of the ADAS-Cog13 total score (ranging from 0 to 85, with higher scores indicating worse cognitive performance) and the ADCS-ADL-MCI total score (ranging from 0 to 53, with lower scores indicating worse daily function). Therefore, the iADRS-MCI total score was calculated as [-1(ADAS-Cog13 score)+85] + ADCS-ADL-MCI score, ranging from 0 to 138, with lower scores indicating worse performance.

Baseline (Day 1), Week 104

二次結果の測定

結果測定
メジャーの説明
時間枠
Double-blind (DB) Treatment Period: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive, 13-item Version (ADAS-Cog13) Total Score at Week 104
時間枠:Baseline (Day 1), Week 104

The ADAS-Cog was a rater administered instrument that was designed to assess the severity of dysfunction in cognition characteristic of persons with Alzheimer's Disease (AD). The ADAS-Cog13 item scale includes all items from the original ADAS-Cog11 (consisting of 11 tasks measuring the disturbances of memory, language, praxis, attention, and other cognitive abilities, often referred to as the core symptoms of AD) in addition of number cancellation task and a delayed free recall task, for a total of 85 points (0 to 85), with higher scores indicating worse cognitive performance.

Baseline (Day 1), Week 104
Double-blind (DB) Treatment Period: Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living for Mild Cognitive Impairment (ADCS-ADL-MCI) Total Score at Week 104
時間枠:Baseline (Day 1), Week 104

The ADCS-ADL-MCI was a functional measure based on information provided by the study partner that describes the performance of participants in several activities of daily living. The ADCS-ADL-MCI scale consists of 17 instrumental items (example; shopping, preparing meals, using household appliances, etc) and 1 basic item (getting dressed). The ADCS-ADL-MCI scale version used in this study comprises 24 items of which 18 items are used for the standard analysis. The total score ranges from 0 to 53 with higher scores indicating less impairment. A positive change from baseline indicates healthy functioning while a negative change from baseline indicates a decline in independent functioning.

Baseline (Day 1), Week 104
Double-blind (DB) Treatment Period: Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at Week 88
時間枠:Baseline (Day 1), Week 88

The RBANS was a battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that are divided into 5 RBANS indices: Immediate memory (list learning and story memory), visuospatial/constructional (figure copy and line orientation), language (picture naming and semantic fluency), attention (digit span and coding) and delayed memory (list recall, list recognition, story recall, and figure recall). Index scores are expressed as an age-adjusted standard score with a normal mean of 100 and an standard deviation (SD) of 15. Sum of index scores was the sum of the 5 index scores, and the Sum of Index Scores was converted to an RBANS total scale index score via a mapping table. The RBANS total scale Index score was a norm-based t-score, based on a distribution with a mean of 100 and an SD of 15. Scores range from 40 to 160. Higher scores indicated better performance.

Baseline (Day 1), Week 88
Double-blind (DB) Treatment Period: Change From Baseline in Each of the 5 Individuals RBANS Indices at Week 88
時間枠:Baseline (Day 1), Week 88

The RBANS was a battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that are divided into 5 RBANS indices: Immediate memory (list learning and story memory), visuospatial/constructional (figure copy and line orientation), language (picture naming and semantic fluency), attention (digit span and coding) and delayed memory (list recall, list recognition, story recall, and figure recall). Index scores are expressed as an age-adjusted standard score with a normal mean of 100 and an standard deviation (SD) of 15. Sum of index scores was the sum of the 5 index scores, and the sum of index scores was converted to an RBANS total scale index score via a mapping table. The RBANS Total Scale Index Score was a norm-based t-score, based on a distribution with a mean of 100 and an SD of 15. Scores range from 40 to 160 each of the index scores. Higher scores indicated better performance.

Baseline (Day 1), Week 88
Double-blind (DB) Treatment Period: Change From Baseline in Each of the 12 Subtests Comprising the RBANS at Week 88
時間枠:Baseline (Day 1), Week 88

The RBANS was a battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that are divided into 5 RBANS indices: Immediate memory (list learning [0-40] and story memory [0-24]), visuospatial/constructional (figure copy [0-20] and line orientation [0-20]), language (picture naming [0-10] and semantic fluency [0-40]), attention (digit span [0-16] and coding [0-89]) and delayed memory (list recall [0-10], list recognition [0-20], story recall [0-12], and figure recall [0-20]). Index scores are expressed as an age-adjusted standard score with a normal mean of 100 and an SD of 15. Sum of index scores was the sum of the 5 index scores, and the Sum of Index Scores was converted to an RBANS total scale index score via a mapping table. Scores range from 40 to 160. Higher scores indicated better performance.

Baseline (Day 1), Week 88
Double-blind (DB) Treatment Period: Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at Week 104
時間枠:Baseline (Day 1), Week 104

The CDR was a subjectively rated outcome measure that serves as a global clinical staging instrument. Six domains were assessed and then synthesized to assign a Global CDR score. It included 3 cognitive and 3 functional domains: 1) memory, 2) orientation, 3) judgment and problem solving, 4) involvement in community affairs, 5) home and hobbies, and 6) personal care based on the CDR interview. The CDR was scored 2 ways yielding a global CDR score (CDR-GS and CDR-SB). CDR was an ordinal parameter (scale 0 [least impairment] to 3 [severe impairment]). The CDR-SB was the sum of the 6 domains which ranged from 0 (least impairment) to 18 (severe impairment). Higher scores indicated worse disease state.

Baseline (Day 1), Week 104
Double-blind (DB) Treatment Period: Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Week 104
時間枠:Baseline (Day 1), Week 104

The NPI was a measure of psychobehavioral disturbances, assessing the frequency and severity of disturbances in 12 domains, based on a caregiver interview. For each domain, there was also an assessment of caregiver burden. Frequency for each domain was rated on a 4-point scale (from 1=rarely to 4=very often) and severity on a 3-point scale (from 1=mild to 3=severe), with the score for each domain being the product of the frequency and severity scores, such that each domain was scored from 1 to 12. The NPI total score was the sum of the 12 domain scores, ranged from 0 (best) to 144 (worst). Higher score indicated worst psychobehavior.

Baseline (Day 1), Week 104
Double-blind (DB) Treatment Period: Percentage of Participants With Progression From Clinical Dementia Rating-Global Score (CDR-GS) 0 to 0.5 or Higher, 0.5 to 1 or Higher, and 1 to 2 or Higher
時間枠:From baseline (Day 1) up to Week 104

Percentage of participants with progression from CDR-GS 0 to 0.5 or higher, 0.5 to 1 or higher, and 1 to 2 or higher was reported. The CDR was a subjectively rated outcome measure that serves as a global clinical staging instrument. Six domains were assessed and then synthesized to assign a Global CDR score. It included 3 cognitive and 3 functional domains: (1) memory, (2) orientation, (3) judgment and problem solving, (4) involvement in community affairs, (5) home and hobbies, and (6) personal care based on the CDR interview. CDR was scored 2 ways yielding a global CDR score (CDR-GS and CDR-SB). CDR was an ordinal parameter (scale 0 [least impairment] to 3 [severe impairment]). The CDR-GS was derived based on an algorithm and was scored of 0 (normal), 0.5 (very mild dementia), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia). Score ranges from 0 to 3 and a high score on CDR-GS indicated a high disease severity.

From baseline (Day 1) up to Week 104
Double-blind (DB) Treatment Period: Change From Baseline in Brain Tau Burden as Measured by Tau Positron Emission Tomography (PET) at Week 104
時間枠:Baseline (Day 1), Week 104

Change from baseline in brain tau burden (tau naive composite Region of interest [ROI] standardized uptake value ratio [SUVR], cerebral cortex ROI SUVR, meta temporal ROI SUVR, spatial progression of tauopathy [SPOT] volume over cerebral cortex ROI) as measured by tau PET was reported. For tau naive ROI method, tau PET brain scans were assessed to measure change in SUVR over regions without evidence of tau burden at baseline (that is, within 1 standard deviation of a cognitively normal amyloid negative reference population). For SPOT method, tau PET brain scans were assessed to quantify extent of spread of tau by measuring difference in volume of elevated tau PET burden (defined as exceeding an SUVR threshold of 1.2) in cerebral cortex brain region at follow up versus that at baseline. Tau PET brain scans were assessed to measure spread of tau tangles using SUVR in cerebral cortex, meta temporal brain region, respectively.

Baseline (Day 1), Week 104
Double-blind (DB) Treatment Period: Change From Baseline in Cerebrospinal Fluid (CSF) Concentrations of Total, Free, and Bound p217+Tau Fragments at Week 104
時間枠:Baseline (Day 1), Week 104

Change from baseline in CSF concentration of total, free, and bound p27+tau fragments at Week 104 was reported.

Baseline (Day 1), Week 104
Double-blind (DB) Treatment Period: Cerebrospinal Fluid (CSF) Concentrations of JNJ-63733657
時間枠:Weeks 52, 104, and 208

CSF concentration of JNJ-63733657 was reported.

Weeks 52, 104, and 208
Double-blind (DB) Treatment Period: Serum Concentrations of JNJ-63733657
時間枠:Baseline (Day 1), Weeks 4, 8, 12, 16, 20, 24, 36, 52, 76, 104, 128, 156, and 180

Serum concentration of JNJ-63733657 was reported.

Baseline (Day 1), Weeks 4, 8, 12, 16, 20, 24, 36, 52, 76, 104, 128, 156, and 180
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent JNJ-63733657 Antidrug Antibodies (ADAs) in Serum
時間枠:Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

Number of participants with treatment-emergent JNJ-63733657 ADA in serum was reported. Any ADAs occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. Participants with treatment-emergent antibodies to JNJ-63733657 included participants with treatment-induced antibodies to JNJ-63733657 and treatment-boosted antibodies to JNJ- 63733657.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
時間枠:Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Any AE occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
時間枠:Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Serious adverse event (SAE) was any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. Any SAE occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)
時間枠:Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Treatment-emergent AESIs were collected in the eCRF and examined separately, grouped in the following categories including: hepatobiliary disorders/Liver enzyme abnormality, and Infusion-related reactions. Any AESI occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants Who Discontinued Study Treatment Due to AEs
時間枠:Baseline (Day 1) up to Week 232

Number of participants who discontinued the study treatment due to AE was reported.

Baseline (Day 1) up to Week 232
Double-blind (DB) Treatment Period: Change From Baseline in 12-lead Electrocardiogram (ECG) Parameter: ECG Mean Heart Rate Supine
時間枠:Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180

Change from baseline in 12-lead ECG parameter (ECG mean heart rate supine) was reported.

Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
Double-blind (DB) Treatment Period: Change From Baseline in 12-lead ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcB Interval, QTcF Interval, QTcL Interval, and RR Interval
時間枠:Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180

Change from baseline in 12-lead ECG parameter (PR interval, QRS duration, QT interval, QTcB interval, QTcF interval, QTcL interval and RR interval) was reported.

Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormalities in Laboratory Parameters
時間枠:Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

Number of participants with treatment-emergent abnormalities in laboratory parameters (hematology, chemistry and urinalysis) were reported. Laboratory abnormalities meeting with lower limit of the normal range (LLN) and upper limit of the normal range (ULN) was reported. Any laboratory abnormalities occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormal Findings in Neurological Examination
時間枠:Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

Number of participants with treatment-emergent abnormal findings in neurological examination (mental state, cranial nerves, motor ability: strength, tone, involuntary movements, coordination: finger-to-nose, gai, postural reflexes, sensation: proprioception, cold, light touch, deep tendon reflexes) was reported. Abnormalities in neurological examination was determined by the investigator. Any neurological abnormalities occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormal Findings in Physical Examination
時間枠:Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

Number of participants with treatment-emergent abnormal findings in physical examination (general appearance, skin, eye, ear, nose, throat, heart, head, neck, thyroid, chest, lung, abdomen, musculoskeletal, breast, neurological) was reported. Abnormal findings in physical examination was determined by the investigator. Any physical abnormalities occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Potentially Clinically Significant Vital Signs
時間枠:Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)

Number of participants with treatment-emergent potentially clinically significant vital signs including systolic blood pressure (standing and supine: less than (<) 90 millimeters of mercury (mmHg) and greater than (>) 180 mmHg), diastolic blood pressure (standing and supine: <50 mmHg and >105 mmHg), pulse (<45 bpm to >120 bpm), temperature (<35 degree Celsius and >38 degree Celsius) and weight (decrease of >=10% relative to baseline and increase of >=10% relative to baseline) were reported. Any clinically significant vital sign occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent.

Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
Double-blind (DB) Treatment Period: Number of Participants With Brain Magnetic Resonance Imaging (MRI) Safety Findings
時間枠:From Day 1 up to Week 245

Number of participants with brain MRI safety findings was reported. MRI safety-related observations from the central imaging vendor including vasogenic edema, cerebral macrohemorrhages, cerebral superficial siderosis and other findings was reported.

From Day 1 up to Week 245
Double-blind (DB) Treatment Period: Number of Participants With Shift From Baseline in Suicidal Ideation or Suicidal Behavior as Assessed by Columbia Suicidality Severity Rating Scale (C-SSRS)
時間枠:Baseline (Day 1) up to Week 245

C-SSRS was a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (suicidal ideation without plan and intent), 4 (suicidal ideation intent to act without plan), and 5 (suicidal ideation with plan and intent). Suicidal behavior was classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt [non-fatal]), and 10 (suicide). Total score from 10 categories was summarized into 3 categories: No suicidal ideation or behavior(0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranged from 0 to 10. Higher scores indicated more severe suicidal ideation and behavior.

Baseline (Day 1) up to Week 245

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年1月6日

一次修了 (実際)

2025年10月17日

研究の完了 (実際)

2026年3月3日

試験登録日

最初に提出

2020年11月5日

QC基準を満たした最初の提出物

2020年11月5日

最初の投稿 (実際)

2020年11月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月5日

QC基準を満たした最後の更新が送信されました

2026年10月14日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • CR108832
  • 2020-000116-30 (EudraCT番号)
  • 63733657ALZ2002 (その他の識別子:Janssen Research & Development, LLC)
  • 2022-501188-42-00 (レジストリ識別子:EUCT number)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する